Prostacyclin and cerebral circulation

  • E. S. Gabrielian
  • S. E. Akopov


Maintenance of a metabolically adequate cerebral blood flow is a remarkable property of the cerebral circulation conditioned by a cascade of intricate interactions of neurohumoral origin and by a complex of interactions between the vessel wall and blood, first of all platelets. Determination of the vessel wall capacity to synthesize prostacyclin (PGI2) and assessment of its highly aggregatory and vasodilator effect on the one hand, and synthesis of thromboxane A2 (TXA2), a prostacyclin antagonist, in platelets on the other, revealed not only a biochemical community of structural and functional organization of two very different systems, but also made it possible to approach, from a new standpoint, the problems of regulation, pathogenesis of disturbances and pharmacological correction of regional circulation (Samuelsson et al., 1978; Moncada &; Vane, 1979).


Human Serum Albumin Basilar Artery Cerebral Circulation Cerebral Vessel Vascular Segment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. FORSTER, C., WHALLEY, E.T., MOHAN, J. &;amp; DUTTON, J. (1980). Vascular smooth muscle response to fibrinogen degradation products and 5-hydroxytryptamine: possible role in cerebral vasospasm in man. Br. J. clin Pharmac., 10, 231–236.CrossRefGoogle Scholar
  2. HORNSTRA, G., HADDEMAN, E. &;amp; DON, J.A. (1979). Blood platelets do not provide endoperoxides for vascular prostacyclin production. Nature, 279, 66–68.PubMedCrossRefGoogle Scholar
  3. KOBATAKE, K., SHINOHARA, Y. &;amp; YAMAMOTO, M. (1979). Red cell aggregation in occlusive cerebrovascular disease. Acta neurol. scand., 60, 612–613.Google Scholar
  4. MARKOSSIAN, R.A., POPOV, E.G., POZIN, E.Y. & RADIN, A.Y. (1979). A new regulation mechanism of thrombocyte functional state. In Current Problems of Haemostasiology. pp. 110–115, Moscow.Google Scholar
  5. MIKHAILIDIS, D.P., MIKHAILIDIS, A.M. & DANDONA, P. (1982). Effect of human plasma proteins on stabilization of platelet anti-aggregatory activity of prostacyclin. Ann. clin. Biochem., 19, 241–244.PubMedCrossRefGoogle Scholar
  6. MONCADA, S. & VANE, J.R. (1979). The role of prostacyclin in vascular tissue. Fedn Proc., 38, 66–71.Google Scholar
  7. MOSKOWITZ, M.A. & COUGHLIN, S.R. (1981). Clinical applications of prostaglandins and their inhibitors. Stroke,12, 882–886.PubMedCrossRefGoogle Scholar
  8. SAMUELSSON, B., GOLDINE, M. & GRANSTRÖM, E. (1978). Prostaglandins and Thromboxanes. In Ann. Rev. Biochem., 47, pp. 997–1029.PubMedCrossRefGoogle Scholar
  9. SCHMIDT, K.G. & RASMUSSEN, J. W. (1979). Preparation of platelet suspensions from whole blood in buffer. Scand. J. Haematol., 23, 88–96.PubMedCrossRefGoogle Scholar
  10. TERRAGNO, N.A. & TERRAGNO, A. (1979). Prostaglandin metabolism in the fetal and maternal vasculature. Fedn Proc., 38, 75–77.Google Scholar
  11. WILLEMS, C., STEL, H.V., VAN AKEN, W.G. & VAN MOURIK, J. (1983). Binding and inactivation of prostacyclin (PGI2) by human erythrocytes. J. Haematol., 54, 43–52.CrossRefGoogle Scholar

Copyright information

© Macmillan Publishers Limited 1984

Authors and Affiliations

  • E. S. Gabrielian
    • 1
  • S. E. Akopov
    • 1
  1. 1.Yerevan Medical InstituteYerevanArmenia

Personalised recommendations